Safety and Efficacy of YPEG-rhG-CSF in Cancer Patients Receiving Chemotherapy

Conditions

• Non Small Cell Lung Cancer
• Breast Cancer

Interventions

• DRUG: YPEG-rhG-CSF, 20μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle
• DRUG: YPEG-rhG-CSF, 30μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle
• DRUG: YPEG-rhG-CSF, 45μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle
• DRUG: PEG-rhG-CSF, 100μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle

Sponsor

Xiamen Amoytop Biotech Co., Ltd.